Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer

Surgery (United States)

Volumn 157, Issue 1, 2015, Pages 119-125

  Niederer Wüst, Séverine M ^a   Jochum, Wolfram ^b   Förbs, Diana ^b   Brändle, Michael ^c   Bilz, Stefan ^c   Clerici, Thomas ^a   Oettli, René ^a   Müller, Joachim ^a   Haile, Sarah R ^d   Ess, Silvia ^a   Stoeckli, Sandro J ^a   Broglie, Martina A ^a  

^a Department of Otorhinolaryngology Head and Neck Surgery Kantonsspital St Gallen ^*  (Switzerland)

^b Institute of Pathology   (Switzerland)

^c Division of Endocrinology and Diabetes   (Switzerland)

^d Clinical Trials Unit   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; RADIOACTIVE IODINE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; AGGRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; DISEASE SPECIFIC SURVIVAL; EXON; FEMALE; GENE MUTATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; REVIEW; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; CARCINOMA; EPIDEMIOLOGY; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SWITZERLAND; THYROID GLAND; THYROID TUMOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SWITZERLAND; THYROID GLAND; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84919459659     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2014.07.015     Document Type: Review

References (54)

1. K.T. Tang, and C.H. Lee BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications J Chin Med Assoc 73 2010 113 128
2. F.D. Gilliland, W.C. Hunt, D.M. Morris, and C.R. Key Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991 Cancer 79 1997 564 573
3. J. Robbins, M.J. Merino, J.D. Boice Jr., E. Ron, K.B. Ain, and H.R. Alexander Thyroid cancer: a lethal endocrine neoplasm Ann Intern Med 115 1991 133 147
4. D.P. Byar, S.B. Green, P. Dor, E.D. Williams, J. Colon, and H.A. van Gilse A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group Eur J Cancer 15 1979 1033 1041
5. I.D. Hay, C.S. Grant, W.F. Taylor, and W.M. McConahey Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system Surgery 102 1987 1088 1095
6. B. Cady, and R. Rossi An expanded view of risk-group definition in differentiated thyroid carcinoma Surgery 104 1988 947 953
7. I.D. Hay, E.J. Bergstralh, J.R. Goellner, J.R. Ebersold, and C.S. Grant Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989 Surgery 114 1993 1050 1057 discussion 1057-8
8. C. Wittekind, C. Compton, P. Quirke, I. Nagtegaal, S. Merkel, and P. Hermanek A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status Cancer 115 2009 3483 3488
9. M.N. Nikiforova, and Y.E. Nikiforov Molecular diagnostics and predictors in thyroid cancer Thyroid 19 2009 1351 1361
10. M. Xing BRAF mutation in thyroid cancer Endocr Relat Cancer 12 2005 245 262
11. L. Fugazzola, E. Puxeddu, N. Avenia, C. Romei, V. Cirello, and A. Cavaliere Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature Endocr Relat Cancer 13 2006 455 464
12. J.H. Lee, E.S. Lee, and Y.S. Kim Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis Cancer 110 2007 38 46
13. M. Xing, W.H. Westra, R.P. Tufano, Y. Cohen, E. Rosenbaum, and K.J. Rhoden BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer J Clin Endocrinol Metab 90 2005 6373 6379
14. S. Lassalle, V. Hofman, M. Ilie, C. Butori, A. Bozec, and J. Santini Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications Curr Med Chem 17 2010 1839 1850
15. D. Handkiewicz-Junak, A. Czarniecka, and B. Jarzab Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions Mol Cell Endocrinol 322 2010 8 28
16. M. Xing BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications Endocr Rev 28 2007 742 762
17. T.H. Kim, Y.J. Park, J.A. Lim, H.Y. Ahn, E.K. Lee, and Y.J. Lee The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis Cancer 118 2012 1764 1773
18. E. Kebebew, J. Weng, J. Bauer, G. Ranvier, O.H. Clark, and Q.Y. Duh The prevalence and prognostic value of BRAF mutation in thyroid cancer Ann Surg 246 2007 466 470 discussion 470-1
19. R. Elisei, C. Ugolini, D. Viola, C. Lupi, A. Biagini, and R. Giannini BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study J Clin Endocrinol Metab 93 2008 3943 3949
20. Y. Ito, H. Yoshida, R. Maruo, S. Morita, T. Takano, and M. Hirokawa BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients Endocr J 56 2009 89 97
21. J.Y. Lim, S.W. Hong, Y.S. Lee, B.W. Kim, C.S. Park, and H.S. Chang Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer; a subgroup analysis of 3130 cases in a single center Thyroid 23 2013 1423 1430
22. D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, and S.J. Mandel Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 19 2009 1167 1214
23. F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J.W. Smit, and W. Wiersinga European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium Eur J Endocrinol 154 2006 787 803
24. M.G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou, and G. Cevenini Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients Eur J Endocrinol 165 2011 441 446
25. H. Namba, M. Nakashima, T. Hayashi, N. Hayashida, S. Maeda, and T.I. Rogounovitch Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers J Clin Endocrinol Metab 88 2003 4393 4397
26. D. Barbaro, R.M. Incensati, G. Materazzi, G. Boni, M. Grosso, and E. Panicucci The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis Endocrine 45 2013 462 468
27. A. Zoghlami, F. Roussel, J.C. Sabourin, J.M. Kuhn, J.P. Marie, and D. Dehesdin BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity Eur Ann Otorhinolaryngol Head Neck Dis 131 2014 7 13
28. L. Fugazzola, D. Mannavola, V. Cirello, G. Vannucchi, M. Muzza, and L. Vicentini BRAF mutations in an Italian cohort of thyroid cancers Clin Endocrinol (Oxf) 61 2004 239 243
29. E. Baldini, S. Sorrenti, C. Tuccilli, N. Prinzi, C. Coccaro, and A. Catania Emerging molecular markers for the prognosis of differentiated thyroid cancer patients Int J Surg 12 Suppl 1 2014 S52 S56
30. M. Xing, A.S. Alzahrani, K.A. Carson, D. Viola, R. Elisei, and B. Bendlova Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer JAMA 309 2013 1493 1501
31. C. Li, P. Aragon Han, K.C. Lee, L.C. Lee, A.C. Fox, and T. Beninato Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers J Clin Endocrinol Metab 98 2013 3702 3712
32. J.K. Nam, C.K. Jung, B.J. Song, D.J. Lim, B.J. Chae, and N.S. Lee Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg 203 2012 436 441
33. J. Zidan, D. Karen, M. Stein, E. Rosenblatt, W. Basher, and A. Kuten Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival Cancer 97 2003 1181 1185
34. S.O. Sebastian, J.M. Gonzalez, P.P. Paricio, J.S. Perez, D.P. Flores, and A.P. Madrona Papillary thyroid carcinoma: prognostic index for survival including the histological variety Arch Surg 135 2000 272 277
35. A.H. Mendelsohn, D.A. Elashoff, E. Abemayor, and M.A. St John Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg 136 2010 1055 1061
36. H.W. Lin, and N. Bhattacharyya Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival Laryngoscope 120 2010 712 716
37. I. Ganly, T. Ibrahimpasic, M. Rivera, I. Nixon, F. Palmer, and S.G. Patel Prognostic implications of papillary thyroid carcinoma with tall-cell features Thyroid 24 2014 662 670
38. J.J. Michels, M. Jacques, M. Henry-Amar, and S. Bardet Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma Hum Pathol 38 2007 212 219
39. S. Jalisi, T. Ainsworth, and M. Lavalley Prognostic outcomes of tall cell variant papillary thyroid cancer: a meta-analysis J Thyroid Res 2010 2010 325602
40. Y. Ito, M. Hirokawa, T. Uruno, M. Kihara, T. Higashiyama, and Y. Takamura Prevalence and biological behaviour of variants of papillary thyroid carcinoma: experience at a single institute Pathology 40 2008 617 622
41. M. Xing Prognostic utility of BRAF mutation in papillary thyroid cancer Mol Cell Endocrinol 321 2010 86 93
42. C. Nucera, J. Lawler, and S. Parangi BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression Cancer Res 71 2011 2417 2422
43. C. Mesa Jr., M. Mirza, N. Mitsutake, M. Sartor, M. Medvedovic, and C. Tomlinson Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling Cancer Res 66 2006 6521 6529
44. J.C. Ricarte-Filho, M. Ryder, D.A. Chitale, M. Rivera, A. Heguy, and M. Ladanyi Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 Cancer Res 69 2009 4885 4893
45. G. Riesco-Eizaguirre, P. Gutierrez-Martinez, M.A. Garcia-Cabezas, M. Nistal, and P. Santisteban The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane Endocr Relat Cancer 13 2006 257 269
46. C. Durante, E. Puxeddu, E. Ferretti, R. Morisi, S. Moretti, and R. Bruno BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism J Clin Endocrinol Metab 92 2007 2840 2843
47. A. Guerra, M.R. Sapio, V. Marotta, E. Campanile, S. Rossi, and I. Forno The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma J Clin Endocrinol Metab 97 2012 517 524
48. B.H. Lang, C.Y. Lo, W.F. Chan, K.Y. Lam, and K.Y. Wan Staging systems for papillary thyroid carcinoma: a review and comparison Ann Surg 245 2007 366 378
49. J.D. Prescott, P.M. Sadow, R.A. Hodin, L.P. Le, R.D. Gaz, and G.W. Randolph BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence Surgery 152 2012 984 990
50. C. Eloy, J. Santos, P. Soares, and M. Sobrinho-Simoes The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases Virchows Arch 459 2011 265 276
51. S. Cheng, S. Serra, M. Mercado, S. Ezzat, and S.L. Asa A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior Clin Cancer Res 17 2011 2385 2394
52. L. Paulson, M. Shindo, K. Schuff, and C. Corless The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma Arch Otolaryngol Head Neck Surg 138 2012 44 49
53. G. Sassolas, Z. Hafdi-Nejjari, A. Ferraro, M. Decaussin-Petrucci, B. Rousset, and F. Borson-Chazot Oncogenic alterations in papillary thyroid cancers of young patients Thyroid 22 2012 17 26
54. V. Sancisi, D. Nicoli, M. Ragazzi, S. Piana, and A. Ciarrocchi BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas J Clin Endocrinol Metab 97 2012 E1745 E1749